Research theme for competitive and other funds (4)：
2022 - 2025 PAI-1・免疫チェックポイント相互阻害による新規免疫療法の開発
2020 - 2022 LL37 might promote local invasion of melanoma by the stimulation of melanoma cells and tumor-associated macrophages
2016 - 2019 Development of novel immune therapy for melanoma by targeting tumor associated macrophages
2016 - 2018 Possible mechanisms of induction of immunotolerance in appocrine-origin skin tumors
Papers (141)：
Taku Fujimura, Koji Yoshino, Hiroshi Kato, Satoshi Fukushima, Yasuhiro Fujisawa, Shigeto Matsushita, Hisashi Uhara, Daiki Rokunohe, Tatsuya Takenouchi, Takeo Maekawa, et al. Phase III Study Investigating the Safety and Efficacy of TM5614 in Combination With Nivolumab for the Treatment of Unresectable Malignant Melanoma: Protocol. Experimental dermatology. 2026. 35. 1. e70202
Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoru Mizuhashi, Takamichi Ito, Takeo Maekawa, Shoichiro Ishizuki, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, et al. Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes. Cancers. 2024. 16. 15
Taku Fujimura, Koji Yoshino, Hiroshi Kato, Satoshi Fukushima, Shoichiro Ishizuki, Atsushi Otsuka, Shigeto Matsushita, Ryo Amagai, Yusuke Muto, Emi Yamazaki, et al. Phase II, multicenter study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-PD-1 antibody-refractory malignant melanoma: TM5614-MM trial. The British journal of dermatology. 2024
Taku Fujimura, Koji Yoshino, Motoki Nakamura, Hiroshi Kato, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Shigeto Matsushita, Ryo Amagai, Emi Yamazaki, et al. Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol. Experimental dermatology. 2023
Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Koji Yoshino, Hiroshi Uchi, Shigeto Matsushita, et al. Adverse events associated with postoperative outcomes of adjuvant anti-PD-1 antibody therapy in both acral and non-acral cutaneous melanomas: A multicenter, observational, post hoc analysis study. The Journal of dermatology. 2023
